Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
Phase 4
Completed
- Conditions
- Glaucoma
- Interventions
- Registration Number
- NCT00519753
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 522
Inclusion Criteria
- Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Age related.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description DuoTrav Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav) One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
- Primary Outcome Measures
Name Time Method Change in intraocular pressure at 12 weeks from travoprost prior therapy (baseline) Baseline and 12 weeks
- Secondary Outcome Measures
Name Time Method Change in intraocular pressure at 12 weeks from other prior therapies (baseline) 12 weeks
Trial Locations
- Locations (1)
Mainz
🇩🇪Mainz, Germany